Novartis Pharmaceuticals Corporation | Novartis | wage and hour violation | 2014 | MI-LEO | $13,000 |
Novartis Pharmaceuticals Corporation | Novartis | wage and hour violation | 2014 | MI-LEO | $5,885 |
BIOGEN IDEC, INC. | Biogen | workplace safety or health violation | 2014 | OSHA | $7,500 |
SANOFI PASTEUR INC. | Sanofi | workplace safety or health violation | 2014 | OSHA | $7,000 |
Pfizer Pharmaceuticals, LLC | Pfizer | environmental violation | 2014 | EPA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $728,000 |
GLAXOSMITHKLINE, LLC | GlaxoSmithKline | environmental violation | 2014 | EPA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $317,550 |
IMO SANOFI PASTEUR | Sanofi | environmental violation | 2014 | EPA | $77,643 |
GLAXOSMITHKLINE VACCINES | GlaxoSmithKline | environmental violation | 2014 | EPA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $172,900 |
Advanced Sterilization Products, Div of Ethicon | Johnson & Johnson | environmental violation | 2014 | EPA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $136,800 |
Advanced Sterilization Products, a division of Ethicon Inc. | Johnson & Johnson | drug or medical equipment safety violation | 2013 | FDA | $1,200,000 |
King Pharmaceuticals LLC | Pfizer | environmental violation | 2013 | EPA | $2,200,000 |
Teva Pharmaceuticals USA Inc. | Teva Pharmaceutical Industries | environmental violation | 2013 | EPA | $2,250,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | FDA | $2,200,000,000 |
Wyeth Pharmaceuticals Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | FDA | $490,900,000 |
Par Pharmaceutical Companies Inc. | Endo International | off-label or unapproved promotion of medical products | 2013 | FDA | $45,000,000 |
EMD Millipore Corporation | Merck KGaA (EMD) | environmental violation | 2013 | EPA | $2,681,500 |
Ranbaxy USA Inc. | Sun Pharmaceuticals | drug or medical equipment safety violation | 2013 | FDA | $500,000,000 |
Abbott Laboratories | Abbott Laboratories | False Claims Act and related | 2013 | DOJ_CIVIL | $5,475,000 |
Genzyme Corp. | Sanofi | False Claims Act and related | 2013 | DOJ_CIVIL | $22,280,000 |
ISTA Pharmaceuticals, Inc. | Bausch Health | False Claims Act and related | 2013 | DOJ_CIVIL | $33,500,000 |
Amgen Inc. | Amgen | False Claims Act and related | 2013 | DOJ_CIVIL | $24,900,000 |
Novartis Pharmaceuticals | Novartis | employment discrimination | 2013 | OFCCP | $51,594 |
Mallinckrodt LLC | Mallinckrodt | False Claims Act and related | 2013 | USAO | $3,500,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | USAO | $410,000,000 |
Actavis Kadian, LLC | AbbVie | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $116,703 |
Intermune, Inc. | Roche | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $5,641 |
Intermune, Inc. | Roche | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $16,215 |
SIGMA-ALDRICH INC | Merck KGaA (EMD) | aviation safety violation | 2013 | FAA | $8,000 |
SIGMA-ALDRICH | Merck KGaA (EMD) | aviation safety violation | 2013 | FAA | $11,000 |
Wyeth | Pfizer | benefit plan administrator violation | 2013 | private lawsuit-federal | $2,000,000 |
Abbott Laboratories | AbbVie | False Claims Act and related | 2013 | LA-AG | $6,200,000 |
Abbott Laboratories, Inc. | Abbott Laboratories | consumer protection violation | 2013 | NY-AG | $25,000 |
Abbott Laboratories, Inc. | AbbVie | False Claims Act and related | 2013 | ID-AG | $1,000,000 |
Amgen, Inc. | Amgen | False Claims Act and related | 2013 | MULTI-AG | $11,000,000 |
Apotex | Apotex Corp. | False Claims Act and related | 2013 | LA-AG | $4,000,000 |
Astellas | Astellas Pharma | False Claims Act and related | 2013 | LA-AG | $1,130,000 |
AstraZeneca | AstraZeneca | off-label or unapproved promotion of medical products | 2013 | KY-AG | $5,500,000 |
Aventis | Sanofi | False Claims Act and related | 2013 | LA-AG | $7,000,000 |
Biovail | Bausch Health | False Claims Act and related | 2013 | LA-AG | $200,000 |
Eisai | Eisai | False Claims Act and related | 2013 | LA-AG | $1,000,000 |
Eli Lilly | Eli Lilly | False Claims Act and related | 2013 | LA-AG | $1,650,000 |
Endo Pharmaceuticals | Endo International | False Claims Act and related | 2013 | TX-AG | $18,170,000 |
Forest Laboratories | AbbVie | False Claims Act and related | 2013 | LA-AG | $3,000,000 |
Forest Laboratories | AbbVie | False Claims Act and related | 2013 | TX-AG | $3,000,000 |
Genzyme Corp. | Sanofi | False Claims Act and related | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $22,280,000 |
Gilead Sciences | Gilead Sciences | False Claims Act and related | 2013 | LA-AG | $250,000 |
ISTA Pharmaceuticals, Inc. | Bausch Health | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $390,253 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | MA-AG | $15,100,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $541,000,000 |
Johnson & Johnson | Johnson & Johnson | False Claims Act and related | 2013 | LA-AG | $10,000,000 |
Lupin Pharmaceuticals | Lupin Limited | False Claims Act and related | 2013 | LA-AG | $750,000 |
Mallinckrodt LLC | Mallinckrodt | False Claims Act and related | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,500,000 |
Merck | Merck | drug or medical equipment safety violation | 2013 | PA-AG | $8,250,000 |
Mylan Specialty L.P. | Viatris | consumer protection violation | 2013 | OR-AG | $250,000 |
Mylan Specialty, L.P. | Viatris | off-label or unapproved promotion of medical products | 2013 | MA-AG | $250,000 |
Novartis | Novartis | False Claims Act and related | 2013 | LA-AG | $7,000,000 |
Novartis Pharmaceuticals Corp. | Novartis | False Claims Act and related | 2013 | ID-AG | $750,000 |
Par Pharmaceutical | Endo International | False Claims Act and related | 2013 | LA-AG | $6,000,000 |
Par Pharmaceutical Companies Inc. | Endo International | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $22,500,000 |
Pernix Therapeutics | Currax Pharmaceuticals | False Claims Act and related | 2013 | LA-AG | $800,000 |
Perrigo | Perrigo | False Claims Act and related | 2013 | LA-AG | $2,000,000 |
Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | MA-AG | $375,000 |
Pfizer Inc. | Pfizer | False Claims Act and related | 2013 | TX-AG | $18,170,000 |
Pharmacia Corporation | Pfizer | False Claims Act and related | 2013 | WI-AG | $29,453,247 |
Ranbaxy | Sun Pharmaceuticals | drug or medical equipment safety violation | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $266,729,715 |
Ranbaxy | Sun Pharmaceuticals | False Claims Act and related | 2013 | LA-AG | $5,000,000 |
Sandoz | Sandoz Group | False Claims Act and related | 2013 | LA-AG | $13,100,000 |
Sanofi US Services, Inc. | Sanofi | kickbacks and bribery | 2013 | MULTI-AG | $617,000 |
Shire | Takeda Pharmaceutical | False Claims Act and related | 2013 | LA-AG | $4,000,000 |
Takeda/Tap Pharmaceuticals | Takeda Pharmaceutical | False Claims Act and related | 2013 | LA-AG | $3,750,000 |
Taro Pharmaceutical Industries | Sun Pharmaceuticals | False Claims Act and related | 2013 | LA-AG | $5,000,000 |
Teva Pharmaceuticals USA | Teva Pharmaceutical Industries | environmental violation | 2013 | MO-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,402,793 |
UCB | UCB | False Claims Act and related | 2013 | LA-AG | $3,350,000 |
Wyeth Pharmaceuticals, Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $257,400,000 |
ELANCO ANIMAL HEALTH A DIV OF ELI LILLY & CO CLINTON LABS | Elanco Animal Health | environmental violation | 2013 | IN-ENV | $20,000 |
E R SQUIBB & SONS LLC | Bristol-Myers Squibb | environmental violation | 2013 | NJ-ENV | $5,950 |
GlaxoSmithKline, LLC | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2013 | MD-AG | $15,000,000 |
DePuy Orthopaedics, Inc. | Johnson & Johnson | drug or medical equipment safety violation | 2013 | private lawsuit-federal | $2,475,000,000 |
Pfizer | Pfizer | drug or medical equipment safety violation | 2013 | private lawsuit-federal | $288,000,000 |
Abbott Cardiovascular Systems, Inc. | Abbott Laboratories | environmental violation | 2013 | CA-SCAQMD | $93,700 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | price-fixing or anti-competitive practices | 2013 | private lawsuit-federal | $11,000,000 |
Aventis Pharmaceuticals Inc. | Sanofi | price-fixing or anti-competitive practices | 2013 | private lawsuit-federal | $800,000 |
GlaxoSmithKline PLC | GlaxoSmithKline | price-fixing or anti-competitive practices | 2013 | private lawsuit-federal | $35,000,000 |
GlaxoSmithKline PLC | GlaxoSmithKline | price-fixing or anti-competitive practices | 2013 | private lawsuit-federal | $150,000,000 |
GlaxoSmithKline PLC | GlaxoSmithKline | price-fixing or anti-competitive practices | 2013 | private lawsuit-federal | $21,500,000 |
Valeant Pharmaceuticals International, Inc. | Bausch Health | price-fixing or anti-competitive practices | 2013 | private lawsuit-federal | $11,750,000 |
Neutrogena Corporation | Johnson & Johnson | consumer protection violation | 2013 | private lawsuit-federal | $1,800,000 |
Merck & Co. | Merck | consumer protection violation | 2013 | private lawsuit-federal | $10,000,000 |
AMGEN SF, LLC | Amgen | workplace safety or health violation | 2013 | OSHA | $5,400 |
AAIPHARMA SERVICES CORP. | Alcami | workplace safety or health violation | 2013 | OSHA | $11,550 |
NOVARTIS CONSUMER HEALTH INC. | Novartis | workplace safety or health violation | 2013 | OSHA | $6,078 |
ANIKA THERAPEUTICS INC. | Anika Therapeutics | workplace safety or health violation | 2013 | OSHA | $5,800 |
EMD MILLLIPORE CORP | Merck KGaA (EMD) | environmental violation | 2013 | EPA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,681,500 |
Celgene Corporation | Bristol-Myers Squibb | environmental violation | 2013 | EPA | $6,035 |
KING PHARMACEUTICALS | Pfizer | environmental violation | 2013 | EPA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,200,000 |
TEVA PHARMACEUTICALS USA INC | Teva Pharmaceutical Industries | environmental violation | 2013 | EPA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,250,000 |
MALLINCKRODT, LLC | Mallinckrodt | environmental violation | 2013 | EPA | $449,740 |
Pfizer Inc. | Pfizer | drug or medical equipment safety violation | 2012 | FDA | $55,000,000 |
GlaxoSmithKline LLC | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2012 | FDA | $3,000,000,000 |
Abbott Laboratories Inc. | AbbVie | off-label or unapproved promotion of medical products | 2012 | FDA | $1,500,000,000 |
Cypress Pharmaceutical Inc. | Currax Pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $2,800,000 |